EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Predictors of High-Flow Nasal Oxygen Success in COVID-19 Respiratory Failure: A Retrospective Observational Cohort Study

Tanaraj Perinpanathan, Katherine Beckett, Rosa McGing, Natalie Lowe, Toby Bonvoisin, Myuran Kuhachandran, Nicholas Easom, Gavin Barlow

COVID · 2026-11-10 · 6 (11) · 200

DOI: 10.3390/covid6110200 ↗
AbstractBibliografische Angaben

Abstract

There is no clear consensus regarding optimal use of oxygen therapy for patients with type 1 respiratory failure secondary to COVID-19. This retrospective observational cohort study evaluates high-flow nasal oxygen (HFNO) delivery in adults with COVID-19 and compares potential predictors of treatment success. Adults receiving HFNO in two tertiary hospitals in Hull, UK, between 1 March 2020 and 1 March 2021 were included. Demographic, clinical, and biochemical data were extracted from hospital records; prognostic scores were calculated retrospectively. HFNO success was defined as an improvement in oxygenation with subsequent discontinuation of HFNO without escalation to non-invasive or mechanical ventilation, or death. In total, 108 patients received HFNO (mean age 64.1 years; 66% male; 94% White/White British). Of the 65% (70/108) considered suitable for ICU, 59% (41/70) achieved HFNO success. Among patients not suitable for ICU (38/108), 24% (9/38) achieved HFNO success. Multivariate analysis identified older age (adjusted OR 1.049, 95% CI 1.015–1.085; p = 0.005) and higher CRP (adjusted OR 1.007, 95% CI 1.002–1.011; p = 0.003) as independent predictors of HFNO failure. The ISARIC 4C score demonstrated 70% positive and 71% negative predictive value for HFNO success (AUROC 0.726, 95% CI 0.628–0.823). These factors may help guide appropriate use of HFNO in patients with COVID-19.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →